WaveMan
WaveMan · Company
DRTS · Alpha Tau Medical Ltd.
> Search tickers & screens ⌘K
LIVE
← All companies

DRTS Alpha Tau Medical (DRTS) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001871321
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
50
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · $127.8K priced

What the filings say about DRTS

Insiders, 180 days
-$1.6M net sold
1 seller · 8% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$71.8K
1 notice

Alpha Tau Medical insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Alpha Tau Medical Ltd. insiders sold a net $1.6M of stock across 12 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.

Insider
Filed
Shares
Value
Since filing
Levy Raphi
Chief Financial Officer
SELL
2026-08-25 SECtraded 2026-08-21
2,871
$43.1K
-12.0%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 11, 2026.
  • The trade is 3.2% of the 90,180 shares held after it.
  • No other insider sold within 30 days.
  • 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Levy Raphi sold about $43.1K of DRTS under a 10b5-1 plan on Aug 21, 2026; 50 funds added in the latest 13F quarter.
Levy Raphi
Chief Financial Officer
SELL
2026-08-12 SECtraded 2026-08-11
17,730
$248.3K
-9.2%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jul 6, 2026.
  • The trade is 19.7% of the 90,180 shares held after it.
  • No other insider sold within 30 days.
  • 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Levy Raphi sold about $248.3K of DRTS on Aug 11, 2026, the largest insider sale at the company on our record; 50 funds added in the latest 13F quarter.
Levy Raphi
Chief Financial Officer
SELL
2026-07-07 SECtraded 2026-07-06
2,270
$31.8K
+3.0%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jul 2, 2026.
  • The trade is 2.5% of the 90,180 shares held after it.
  • No other insider sold within 30 days.
  • 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Levy Raphi sold about $31.8K of DRTS on Jul 6, 2026; 50 funds added in the latest 13F quarter.
Levy Raphi
Chief Financial Officer
SELL
2026-07-06 SECtraded 2026-07-02
17,873
$232.4K
+3.2%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jul 1, 2026.
  • The trade is 19.8% of the 90,180 shares held after it.
  • No other insider sold within 30 days.
  • 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Levy Raphi sold about $232.4K of DRTS on Jul 2, 2026; 50 funds added in the latest 13F quarter.
Levy Raphi
Chief Financial Officer
SELL
2026-07-02 SECtraded 2026-07-01
2,127
$27.7K
-3.1%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 30, 2026.
  • The trade is 2.4% of the 90,180 shares held after it.
  • No other insider sold within 30 days.
  • 50 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Levy Raphi sold about $27.7K of DRTS on Jul 1, 2026; 50 funds added in the latest 13F quarter.
12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 7 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$1.6M over 180 days
-$291.3K over 90 days
below 66% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
50 funds bought in last quarter
below 57% of Medical Devices
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.4% of the float short (float per yahoo 2026-10-26) · 6.6 days to cover · settled 2026-09-30
more than 55% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch DRTS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+225.7%12M
-14%+85%+184%+284%2025-102025-122026-022026-042026-062026-082026-10 2026-08-11 · Levy Raphi sold $248.3K2026-06-30 · Levy Raphi sold $240.0K2026-07-02 · Levy Raphi sold $232.4K2026-06-03 · Levy Raphi sold $190.8K2026-06-25 · Levy Raphi sold $173.6K2026-06-03 · Levy Raphi sold $161.4K2026-06-23 · Levy Raphi sold $142.1K2026-06-25 · Levy Raphi sold $46.4K2026-08-21 · Levy Raphi sold $43.1K2026-07-06 · Levy Raphi sold $31.8K2026-07-01 · Levy Raphi sold $27.7K2026-06-23 · Levy Raphi sold $25.0K2026-08-21 · Raphael (Raphi) Aryeh Levy filed to sell $71.8K2026-07-06 · Levy Raphi filed to sell $264.6K2026-07-02 · Levy Raphi filed to sell $251.6K2026-06-30 · Levy Raphi filed to sell $224.4K2026-06-26 · Levy Raphi filed to sell $201.0K2026-06-23 · Levy Raphi filed to sell $175.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DRTS: institutional holders (13F)

13F holdings, latest reported quarter
Gem Investment Advisors, LLC
1,434,476 sh
$18.0M
HighTower Advisors, LLC
874,994 sh
$11.0M
BOOTHBAY FUND MANAGEMENT, LLC
773,481 sh
$9.7M
Aquamarine Financial (Cayman) Ltd
721,501 sh
$9.1M
Pier Capital, LLC
691,939 sh
$8.7M

Congress trades in DRTS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DRTS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Raphael (Raphi) Aryeh Levy
Filed 2026-08-21
$71.8K
Levy Raphi
Filed 2026-07-06
$264.6K
Levy Raphi
Filed 2026-07-02
$251.6K
Levy Raphi
Filed 2026-06-30
$224.4K
Levy Raphi
Filed 2026-06-26
$201.0K

DRTS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Dunham Small Cap Growth Fund
$844.9K position · as of 2026-07-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.6M sold by insiders over 180 days, 50 funds added last quarter, $71.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

DRTS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Debt to equity
0.00x
long-term debt only, 2023-10-31; equity 2025-12-31
Cash flow to debt
n/a
needs four quarters of operating cash flow
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Enterprise value
$1.1B
market value at close 2026-10-23 on 2025-12-31 shares, plus long-term debt only, 2023-10-31, minus cash 2025-12-31
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122023-10
Operating income-$42.3M-$36.0M-$35.7Mn/a
Net income-$42.6M-$31.8M-$29.2Mn/a
EPS (diluted)-0.53-0.45-0.42n/a
Operating cash flow-$26.7M-$19.8M-$18.0Mn/a
Cash$12.2M$13.7M$12.7Mn/a
Long-term debtn/an/an/a$20.3K
SEC XBRL, fiscal years, as known on 2026-10-27

DRTS Stock Sonar score 4/7 axes

Find similar shapesCompare

DRTS ranks highest on financial health (92nd percentile) and risk and compliance (46th), and lowest on insider conviction (16th), among Medical Devices peers.

Financial health
92
Inputs
  • Debt to equity0.00x · 92 pct, sector of 159
  • Cash flow to debtneeds four quarters of operating cash flow
Insider conviction
16
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.5M · 32 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
43
Inputs
  • Funds adding, latest quarter50 · 43 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
46
Inputs
  • Short interest, % of float+5.4% · 46 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Growth, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DRTS filings, in plain words

Are Alpha Tau Medical insiders buying or selling DRTS?

In the 180 days to 2026-10-27, Alpha Tau Medical insiders were net sellers, a net $1.6M across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of DRTS?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-27, covering $71.8K of stock; the latest, by Raphael (Raphi) Aryeh Levy, was filed 2026-08-21.

Read the full summary

In the 180 days to 2026-10-27, Alpha Tau Medical insiders were net sellers of DRTS, a net $1.6M across purchases and sales reported on Form 4 by 1 seller. 8% of the 12 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-27, covering $71.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies